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Abstract
Tributyltin (TBT) is a widespread environmental contaminant that is present in human blood and 
other tissues. It has been shown to disrupt the immune function of human natural killer (NK) cells 
and to alter the secretion of a number of pro-inflammatory cytokines from immune cells. Secretion 
of both interleukin 1β (IL-1β) and interleukin 6 (IL-6) from human lymphocytes can be increased 
dependent upon the level of TBT exposure. This study shows that the TBT-induced increases in 
secretion of both cytokines are due to TBT-induced increases in the synthesis of these proteins and 
not simply to the release of pre-existing cytokine. Further, the data indicate that these TBT-
induced increases in IL-1β and IL-6 synthesis require MAP kinase signaling pathways. 
Additionally, elevated synthesis of IL-1β and IL-6 seen at the highest exposures to TBT (200, 200, 
50 nM) were accompanied by increases in the mRNA for these cytokines. TBT-induced increases 
in IL-1β and IL-6 mRNAs were also shown to be dependent on MAP kinase signaling. The study 
suggests that TBT has the capacity to increase immune cell production of these 2 important pro-
inflammatory cytokines and that this increase is in part explained by increased mRNA for the 
cytokines.
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Introduction
Due to its multitude of uses as a biocide, tributyltin (TBT) widely contaminates the 
environment and has been found in human tissues including blood (as high as 261 nM in 
blood) (Antizar-Ladislao, 2008; Kannan et al., 1995; Kannan et al., 1999; Whalen et al., 
1999). It was used as an antifouling agent in paints applied to the hulls of ships (Loganathan 
et al., 2001; Loganathan, 2016). This use was banned by the International Convention on the 
Control of Harmful Antifouling Systems on Ships in 2008 (Gipperth, 2009), but is still used 
by countries that are not part of the convention. It is also found in some household goods 
such as siliconized-paper baking parchments and shower curtains (Yamada et al., 1993). 
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TBT exposure can cause increased incidences of tumors and thymic atrophy in mammals 
(Wester et al., 1990; Snoeij et al., 1988) and decrease the ability of human natural killer 
(NK) lymphocytes to destroy tumor cells (Dudimah et al., 2007). Additionally, TBT has 
been shown to alter the secretion of several important pro-inflammatory cytokines from 
human lymphocytes. These include interferon gamma (IFNγ), tumor necrosis factor alpha 
(TNFα), IL-1β, and IL-6 (Hurt et al. 2013; Lawrence et al., 2015; Brown and Whalen, 2015; 
Brown et al., 2018).
IL-1β regulates the inflammatory response and promotes cellular growth, and tissue repair 
(Apte et al., 2002; Arend, 2002; Dinarello, 1996; 2005; 2009). It is produced by monocytes, 
macrophages, T cells, NK cells, neutrophils, keratinocytes, and fibroblasts (Guma et al., 
2009; Burger and Dayer, 2002; Dinarello, 2005; Apte et al., 2002; Voronov et al., 2002). 
IL-1β can act as a stimulator of the production of other pro-inflammatory cytokines, 
including IFNγ and IL-6 (Tosato and Jones, 1990; Cooper et al., 2001; Luo et al., 2003). 
When IL-1β levels are elevated inappropriately it contributes to chronic inflammation 
(Dinarello, 2011). Elevated IL-1β is associated with a number of diseases including multiple 
sclerosis, rheumatoid arthritis, and cancer (Rossi et al., 2012; Choy & Panayi, 2001; Arlt et 
al., 2002; Elaraj et al., 2006; Jin et al., 1997; Lewis and Varghese, 2006; Muerkoster et al., 
2006. A drug that decreases IL-1β levels is an approved treatment for rheumatoid arthritis 
(Dinarello, 2011).
Like IL-1β, IL-6 is a pro-inflammatory cytokine (22–27 kDA) (Kishimoto, 1989) produced 
by a variety of cells types including lymphocytes, monocytes/macrophages, and 
granulocytes (Akira et al., 1993; Li and He, 2006; Hall et al., 2010; Riedemann et al., 2004; 
Zimmermann et al., 2015; 2016). As with IL-1β, inappropriately elevated levels of IL-6 can 
lead to chronic inflammation (Tanaka et al., 2014) and increased IL-6 activity contributes to 
chronic inflammatory diseases such as colon cancer, colitis, rheumatoid arthritis, systemic 
lupus erythematosus, psoriasis, and Crohn’s disease (Gabay, 2006; Atreya et al., 2000; Hurst 
et al., 2001). An antibody to the IL-6 receptor, tocilizumab, has been approved to treat 
rheumatoid arthritis (Tanaka et al., 2014).
TBT has been shown to alter the secretion of both IL-1β and IL-6 from human lymphocytes 
(Brown and Whalen, 2015; Brown et al., 2018). The current study examines whether these 
alterations in secretion are due to changes in the lymphocytes’ synthesis of these cytokines 
or if it is simply due to changes in the secretion of pre-existing cytokine. To address this, 
both secreted and intracellular levels of each cytokine were measured from the same cells in 
response to exposures to TBT. TBT concentrations that caused increases in cytokine 
synthesis were then examined to determine if this reflected an increase in the mRNA for the 
cytokine. Additionally, signaling pathways known to be utilized in cellular production of 
each of the cytokines were examined for potential roles in any TBT-induced increases in 
either cytokine. These included, mitogen activated protein kinases (MAPKs) and nuclear 
factor kappa B (NFκB) (Gaestel et al., 2009).
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PBMCs were isolated from Leukocyte filters (PALL- RCPL or RC2D) obtained from the 
Red Cross Blood Bank Facility (Nashville, TN) as described in Meyer et al., 2005. 
Leukocytes were retrieved from the filters by back-flushing them with sterile PBS 
containing 5 mM disodium EDTA and 2.5% [w/v] sucrose and collecting the eluent. The 
eluent was layered onto Ficoll-Hypaque (1.077g/mL) and centrifuged at 1200g for 30–50 
min. Mononuclear cells were collected and washed with PBS (500g, 10min). Following 
washing, the cells were layered on bovine calf serum for platelet removal. Monocyte-
depleted PBMCs were prepared by incubating the cells in glass Petri dishes (150 × 15 mm) 
at 37 °C and air/CO2, 19:1 for 1.5 h. This cell preparation is referred to as MD-PBMCS 
cells.
Chemical Preparation
Tributyltin chloride (TBT) was purchased from Sigma-Aldrich (96%) (St. Louis, MO). 
Desired concentrations of TBT were prepared by dilution of the stock into cell culture 
media. TBT was a neat standard, dissolved initially in deionized water to give a 1 mM 
solution.
Inhibitor Preparation
Enzyme inhibitors were purchased from Fisher Scientific (Pittsburgh, PA). The stock 
solution for each inhibitor was a 50 mM solution in dimethylsulfoxide (DMSO). Capase-1 
inhibitor II (50 μM), MEK 1/2 pathway inhibitor (PD98059) (50 μM), p38 inhibitor 
(SB202190) (25 μM), JNK pathway inhibitor (JNK X BI78D3) (0.05 μM), and NFκB 
inhibitor (BAY11-7085) (0.3125–1.25 μM) were prepared by dilution of the stock solution 
into cell culture media.
Cell treatments
MD-PBMCs were treated with TBT and appropriate control(s). Following the incubations, 
the cells were pelleted and the supernatants were collected and frozen at −70°C until assay. 
Cell pellets were lysed and stored at −70°C for western blot analysis.
IL-1 β and IL-6 Secretion Assays
IL-1 β and IL-6 levels were measured using the BD OptEIATM Human enzyme-linked 
immunosorbent assay (ELISA) kits (BD-Pharmingen, San Diego, CA).
Cell Lysis
MD-PBMCs (at a concentration of 4–6 million cells/mL) were treated with 2.5–200 nM 
TBT or control for 10 min, 30 min, 6 h, or 24h. Following the treatments, the cells were 
centrifuged, supernatants collected, and the cell pellets lysed using 133 μL of lysis buffer 
(Active motif, Carlsbad, CA). For inhibitor studies, MD-PBMCs (at a concentration of 3 
million cells/mL) were either treated with 5, 10, 25 nM TBT (IL-1β studies) or 50, 100, 200 
nM TBT (IL-6 studies). The cell lysates were stored frozen at −80 °C.
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Cell lysates were run on 10% SDS-PAGE (sodium dodecylsulfate polyacrylamide gel 
electrophoresis) and transferred to a PVDF (polyvinylidene difluoride) membrane. The 
PVDF was immunoblotted with specific primary antibodies: anti-IL-1β, anti-IL-6, and anti-
β actin (Cell Signaling Technologies, Beverly, MA). Antibodies were visualized using an 
ECL chemiluminescent detection system (Amersham, Piscataway, NJ) and UVP Imager. β-
Actin levels were determined for each condition to verify that equal amounts of protein were 
loaded. In addition, the density of each protein band was normalized to β-actin to correct for 
slight differences in protein loading among the lanes.
RNA Isolation and RT-qPCR
RNA from MD-PBMCs (at a concentration of 4–6 million cells/mL) was extracted with 
RNeasy Mini Kit (Qiagen). PCR primers were designed using Primer Express 2.0 (Applied 
Biosystems;). All RT-qPCR assays were conducted using QuantiTect SYBR Green RT-PCR 
kit (Qiagen). Reaction was done in 20 μL containing 50 ng of total RNA and 0.4 μM of each 
primer.




Statistical analysis of the data was performed by using ANOVA and Student’s t test. Data 
were initially compared within a given experimental setup by ANOVA. A significant 
ANOVA was followed by pair wise analysis of control versus exposed data using Student’s t 
test, a p value of less than 0.05 was considered significant.
Results
Effects of TBT Exposures on the Synthesis (Secretion + Intracellular Levels) of IL-1β
10 min exposures to TBT—The effects of 10 min exposures to TBT on intracellular and 
secreted levels of IL-1β were examined in MD-PBMCs from 3 separate donors. There were 
no increases in the synthesis of IL-1β(secretion + intracellular levels) after 10 minutes of 
exposure to TBT (data not shown).
30 min exposures to TBT—Figure 1A summarizes the effects of 30 min exposure to 
TBT on intracellular and secreted IL-1β in MD-PBMCs from 4 separate donors. Cells from 
each of the 4 donors exhibited slight increases in synthesis of IL-1β (the combination of 
fold increase in intracellular + fold increase in secreted IL-1β >1) at one or more TBT 
concentrations. For example, cells from donor F219 showed increases of 1.5, 1.2, 1.4, and 
1.8 fold in IL-1β synthesis with exposures to 200, 10, 5, and 2.5 nM TBT.
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6 h Exposures to TBT—The effects of 6 h exposures to TBT on IL-1β synthesis are 
shown in Figure 1B. As was seen at 30 minutes, cells from all donors exhibited increased 
production (a combined intracellular fold increase + secreted fold increase of greater than 1). 
However, the extent of the increases was somewhat greater than that seen after 30 minutes 
and it occurred at 3 or more exposure concentrations.
24 h Exposures to TBT—The changes in intracellular and secreted IL-1β after 24 h 
exposures to TBT are shown in Figure 1C. When the effects on secretion + intracellular 
levels of IL-1β were examined there was a notable increase in its production in the cells 
from each of the 4 donors. Every TBT exposure caused an increase in production many of 
which were quite large (ranging from 1.1–26.4 fold) indicating that after 24 h of exposure 
TBT stimulates very consistent and quite substantial increases in IL-1β production in MD-
PBMCs.
Effects of Exposures to TBT on the Synthesis of IL-1β by MD-PBMCs Treated with 
Signaling Pathway Inhibitors
Mitogen activated protein kinase kinase (MAP2K), MEK, Inhibitor (PD98059)—
The effects of exposures to 5, 10, and 25 nM TBT synthesis (intracellular + secreted levels) 
of IL-1β from MD-PBMCs where p44/42 MAPK function had been inhibited with PD98059 
are shown in Figure 2A. Cells exposed to TBT when the inhibitor was present showed 
diminished TBT-stimulated synthesis of IL-1β. For instance, when cells from donor F300 
were exposed to 5, 10, and 25 nM TBT in the absence of PD98059 inhibitor there were 4.2, 
4.1, and 8.4 fold increases in IL-1β production. When the inhibitor was present those same 
TBT exposures caused no increase in synthesis at the 5 and 10 nM exposures, and only a 2 
fold increase in IL-1β production at the 25 nM exposure. This same effect was seen in the 
cells from 3 other donors tested. Overall, the results indicate that the p44/42 MAPK pathway 
is being utilized to some extent by TBT to lead to increases in IL-1β synthesis in the cells 
from the majority of donors.
p38 Inhibitor (SB202190)—The effect of p38 MAPK pathway inhibition on TBT-
induced increases in IL-1β synthesis from MD-PBMCs are shown in Figure 2B. All donors 
consistently showed lowered TBT-induced IL-1β synthesis in the presence of SB202190. 
For example, donor F325 showed 2.3, 3.0, and 4.9 fold increases when MD-PBMCs were 
exposed to 5, 10, and 25 nM TBT in the absence of the p38 inhibitor. When the inhibitor 
was present, those same TBT exposures caused 1.5, 2.1, and 1.9 fold change. This indicates 
that the p38 pathway is being utilized by TBT to stimulate IL-1β production.
Nuclear Factor kappa B (NFκB) Inhibitor (BAY 11-7085) and JNK Inhibitor (JNK 
X BI78D3)—In contrast to the results seen with MEK and p38, inhibition of either the 
NFκB pathway or the JNK pathway caused no consistent loss of TBT-induced increases in 
IL-1β synthesis (data not shown). This indicated that neither of these pathways are 
consistently needed for TBT to increase IL-1β synthesis.
Brown et al. Page 5













Effects of Exposures to TBT on IL-1β mRNA Levels in MD-PBMCs
Table 1 shows IL-1β mRNA expression tested in 4 separate donors from MD-PBMCs with 
TBT concentrations ranging from 2.5–200 nM. No changes were seen after 6 h for 3 of the 4 
donors. The effects of 24 h exposures to TBT on IL-1β mRNA levels in MD-PBMCs are 
also shown in Table 1. Higher concentrations of TBT (in the range of 25–200nM) caused 
increased mRNA expression compared to the control for all donors at two or more TBT 
concentrations with fold increases ranging from 1.3–5.3. These results suggest that the TBT-
induced increases in IL-1β synthesis are due to increases in IL-1β mRNA at levels of TBT 
of 25 nM or more.
Effects of TBT Exposures on IL-1β mRNA Levels in MD-PBMCs Treated with p44/42 
(PD98059) and p38 (SB 202190) Pathway Inhibitors
Based on its role in TBT-induced synthesis of IL-1β, we examined if the p44/42 MAPK 
pathway was needed for TBT-induced increases in IL-1β mRNA. Results indicated that 
p44/42 pathway is not consistently utilized by TBT to lead to increased levels of IL-1β 
mRNA (data not shown). However, when the p38 MAPK pathway was inhibited by 
SB202190, TBT-stimulated increases in IL-1β mRNA levels were blocked (Figure 3). The 
ability of TBT to increase IL-1β mRNA was diminished in cells from all donors. There were 
1.2, 1.9, and 1.7 fold increases in IL-1β mRNA when cells were exposed to 50, 100, and 200 
nM TBT in the absence of inhibitor. There were no TBT-induced increases in IL-1β mRNA 
expression when the inhibitor was present at 50 and 200 nM TBT exposures and the increase 
at 100 nM went from 1.9 fold to 1.1 fold (Figure 3). These results were replicated in cells 
from 3 additional donors. This indicates that p38 pathway is needed to cause TBT-induced 
increases of IL-1β mRNA levels.
Effects of TBT exposures on the synthesis (secretion + intracellular levels) of IL-6
10 min exposures to TBT—As was seen with TBT’s effect on IL-1β production, there 
were no consistent increases in IL-6 synthesis seen after a 10 min exposure to TBT (data not 
shown).
30 min exposures to TBT—After a 30 min exposure to TBT, cells from all donors 
showed increases in IL-6 production at a minimum of 3 concentrations. The changes in 
intracellular levels paired with the changes in fold secretion are shown in Figure 4A. These 
results indicate that TBT induces generally small but consistent increases in IL-6 synthesis 
after 30 min of exposure to TBT.
6 h exposures to TBT—When MD-PBMCs from 4 distinct donors were exposed to TBT 
for 6 h there was also typically a small but consistent increase in IL-6 synthesis at 1 or more 
exposure (Figure 4B). This was evidenced by the combined fold increases in intracellular 
and secreted levels being greater than 1. Increases ranged from 1.3 fold for cells from F234 
the 2.5 nM exposure to 9.7 fold for cells from F246 at the 200 nM concentration.
24 h exposures to TBT—Figure 4C shows the effects of 24 h exposure to TBT on 
synthesis of IL-6. Dramatic increases were seen in IL-6 synthesis at the higher TBT 
concentrations of 50, 100, and 200 nM. Fold increases ranged from 28–852 (200 nM TBT). 
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There was not a commensurate increase in the secretion of IL-6 from these cells. This 
indicates that while TBT is able to increase the production of IL-6, it must also be to some 
extent blocking its secretion.
Effects of exposures to TBT on the synthesis of IL-6 by MD-PBMCs treated with Signaling 
Pathway Inhibitors
MEK, Inhibitor (PD98059)—The effects of inhibiting the p44/42 mitogen activated 
protein kinase (MAPK) pathway with PD98059 (50 μM) on TBT-induced increases in IL-6 
synthesis are shown in Figure 5A (shows fold increases in intracellular and secreted levels). 
When this pathway was inhibited, the ability of TBT to stimulate IL-6 synthesis was 
decreased at one or more TBT concentration in cells from all 4 donors. For example, cells 
from donor F325 exposed to 50, 100, and 200 nM TBT in the absence of the inhibitor 
showed 1.6, 2.0, and 4.0 fold increases in IL-6 production. In the presence of inhibitor these 
same cells showed reduced TBT-induced production of IL-6 of 1.1, 1.2, and 2.3 fold at these 
same concentrations. This indicates that the p44/42 MAPK pathway is being utilized to 
some extent by TBT to increase IL-6 production.
p38 Inhibitor (SB202190)—Figure 5B shows the effects of exposures to 50, 100, and 200 
nM TBT on intracellular/secreted levels of IL-6 from MD-PBMCs where p38 MAPK 
function had been inhibited with SB202190. When the inhibitor was present, TBT-
stimulated synthesis of IL-6 was completely blocked in MD-PBMCs from all donors tested. 
For instance, when cells from donor F405 were exposed to 50, 100, and 200 nM TBT in the 
absence of the inhibitor there were 0.9, 1.4, and 3.9 fold increases in IL-6 production and no 
TBT-induced increases in IL-6 production when the inhibitor was present. These results 
indicate that the p38 MAPK pathway is being utilized by TBT to lead to increases in IL-6 
production.
NFκB Inhibitor (BAY 11-7085) and JNK Inhibitor (JNK X BI78D3)—When either 
the NFκB pathway or JNK pathway were inhibited in MD-PBMCs with their respective 
inhibitors, the ability of TBT to increase IL-6 synthesis was not consistently decreased. 
Thus, it appears that as was seen with IL-1β, neither the NFκB pathway nor the JNK 
pathway are consistently used by TBT to induce increases in IL-6 synthesis.
Effects of Exposures to TBT on IL-6 mRNA Levels in MD-PBMCs
The effects of 6 h exposures to TBT on IL-6 mRNA expression in MD-PBMCs are shown in 
Table 2. Tested in cells from 4 separate donors, no statistically significant increases were 
seen at any of the TBT exposures after 6 h. Table 2 also shows the effects of 24 h exposures 
to TBT on IL-6 mRNA levels. Higher concentrations of TBT (100 nM and 200 nM) showed 
increased mRNA expression compared to the control for 3 of the 4 donors. Fold increases at 
the highest TBT concentration were 4.0 fold (F277), 7.5 fold (F266), and 54.7 fold (F322). 
These data indicate that TBT may be increasing IL-6 synthesis, at least in part, by increasing 
the mRNA for IL-6.
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Effects of TBT Exposures on IL-6 mRNA Levels in MD-PBMCs Treated with p44/42 
(PD98059) and p38 (SB 202190) Pathway Inhibitors
Figure 6 shows the effects of p38 MAPK pathway inhibition on TBT-stimulated increases in 
IL-6 mRNA levels. When this pathway was inhibited the ability of TBT to increase IL-6 
mRNA was blocked. Cells showed 1.3, 1.3, and 2.7 fold increases in IL-6 mRNA when 
exposed to 50, 100, and 200 nM TBT in the absence of inhibitor. There were no TBT-
induced increases in IL-6 mRNA expression when the inhibitor was present (Figure 6). This 
result was replicated in cells from 3 additional donors. Thus, TBT-induced increases in IL-6 
mRNA appear to be dependent on the p38 pathway. As was seen with TBT-induced 
increases in IL-1β mRNA, inhibition of the p44/42 pathway with the MEK inhibitor 
(PD98059) did not effect TBT’s ability to increase IL-6 mRNA levels in MD-PBMCs (data 
not shown).
Discussion
TBT has been shown to increase the secretion of IL-1β and IL-6 within 24 h of exposure 
(Brown and Whalen, 2015; Brown et al., 2018). However, it was not clear if TBT-induced 
increases in secretion of IL-1β or IL-6 were due to increased synthesis of the cytokines or 
simply release of pre-existing IL-1β or IL-6. Due to its ability to increase secretion of these 
2 important pro-inflammatory proteins, TBT has the capacity to produce “sterile 
inflammation” (inflammation in the absence of microorganisms, Chen and Nunez, 2010) 
which could then contribute to chronic inflammation. Chronic inflammation is a known 
promoter of a number of disease states including rheumatoid arthritis, Crohn’s disease, 
multiple sclerosis, and cancer (Choy and Panayi, 2001; Dinarello, 2011; Rossi et al., 2012; 
Arlt et al., 2002; Elaraj et al., 2006; Jin et al., 1997; Lewis and Varghese, 2006; Muerkoster 
et al., 2006; Voronov et al., 2002; Chirivi et al., 1996; Vidal-Vanaclocha et al., 1996; Gabay, 
2006; Atreya et al., 2000; Hurst et al., 2001; Culig et al., 2005; Nilsson et al., 2005). If TBT 
is increasing the secretion of existent cytokine in the absence of increased cellular synthesis, 
then increased levels of these cytokines would be somewhat self-limiting. However, if TBT 
is also stimulating immune cells to produce these potent inflammatory proteins, then very 
significant “sterile inflammation” could result in response to TBT exposures.
Thus, intracellular levels and accompanying secretion of IL-1β and IL-6 were examined at 
10 min, 30 min, 6 h, and 24 h. The measurement of both secreted and intracellular levels of 
the cytokine from the same cells made it possible to determine if TBT affected synthesis of 
these 2 cytokines in immune cells. The results indicated that TBT at several exposure levels 
caused small but consistent increases in IL-1β production within 6 h of exposure and these 
changes were very robust after 24 h. Results after 24 h showed that TBT increased IL-1β 
synthesis at every concentration.
The effects of TBT exposures on IL-6 synthesis were similar to those seen with IL-1β in that 
increased IL-6 production was noticeable after 6 h and most clearly seen after 24 h with 
substantial increases seen at every TBT concentration. In contrast to the effect of TBT on 
IL-1β production, the increased production of IL-6 stimulated by TBT was not accompanied 
by increased secretion of the cytokine. This indicates that TBT while greatly activating the 
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synthesis of IL-6 (at higher concentration) is simultaneously having an inhibitory effect on 
its secretion.
Synthesis of both IL-6 and IL-1β is regulated by MAP kinase and NFκB signaling pathways 
(Gaestel et al., 2009). The current studies indicate that TBT is utilizing both the p44/42 and 
p38 pathways to lead to increased IL-1β production, with a greater dependence on the p38 
pathway. The pathway dependence of TBT-induced increases in IL-6 at 50, 100, and 200 nM 
was also examined. As was seen with IL-1β, both the p44/42 and p38 are utilized by TBT to 
lead to increased IL-6 production. The p38 pathway was necessary for TBT-induced 
increases in IL-6 and the p44/42 pathway contributed to TBT-induced increases but was not 
as crucial as p38, similar to what was seen with IL-1β.
The increases that were seen in IL-1β and IL-6 synthesis in response to TBT exposures 
could be due to increased transcription, stabilization of mRNA, increased translation, or a 
combination of these factors. Results indicated that increased mRNA levels of both 
cytokines were generally seen after 24 h at TBT concentrations of 50, 100, and 200 nM. 
However, increased protein levels were seen at all TBT concentrations after 24 h exposures. 
This suggests that an increase in mRNA is at least in part responsible for the TBT-induced 
increases in these 2 cytokines seen at higher TBT concentrations. However, TBT-induced 
increases in the mRNA of either IL-1β or IL-6 do not appear to explain the TBT-induced 
increases in IL-1β and IL-6 synthesis seen at the lower concentrations of TBT. It is possible 
that these increases are due to TBT effects on the translational process. TBT utilizes the 
MAPK pathways for increased production and it is known that MAPKs can lead to increased 
translation due to activation of the eukaryotic initiation factor 4E (eIF4E) (Shveygert et al., 
2010).
As both p44/42 and p38 appear to have a role in the TBT-induced increases in IL-1β and 
IL-6 production, we investigated whether these signaling pathways were required for TBT-
induced increases in IL-1β and IL-6 mRNA expression. The results suggest that p38 
pathway is needed for TBT-induced increases of IL-1β and IL-6 mRNA levels.
In summary, the current study indicates that TBT induces increases in the cellular synthesis 
of both IL-1β and IL-6. Further, it shows that elevated synthesis is detectable within 6 h of 
exposure. TBT causes synthesis of IL-1β, which then leads to increased secretion. In 
contrast, TBT stimulated synthesis of IL-6 but did not increase secretion, indicating that 
TBT causes at least a partial inhibition of IL-6 secretion, which was not seen with IL-1β. 
TBT-induced synthesis of each of these cytokines is primarily dependent on the p38 MAPK 
pathway and to a lesser extent the p44/42 pathway. The highest levels of TBT caused 
increased mRNA for both IL-1β and IL-6, which could account for the TBT-elevated 
synthesis. However, lower concentrations of TBT did not increase the mRNAs for these 
cytokines even though they stimulated the synthesis of the proteins.
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Effects of exposures to TBT on IL-1 β synthesis in monocyte-depleted PBMCs. A) 30 
minute exposure to 0–200 nM TBT. The blots with accompanying secretion data are 
shown for the cells from 4 different donors. An increase in secretion or in intracellular level 
is a number greater than 1; a decrease in secretion compared to the control is a number less 
than 1. The control is arbitrarily set at 1. A combined fold increase (secretion + intracellular) 
greater than 1 indicates an increase in synthesis. B) 6 h exposure to 0–200 nM TBT. The 
blots with accompanying secretion data are shown for the cells from 4 different donors. C) 
24 h exposure to 0–200 nM TBT. The blots with accompanying secretion data are shown 
for the cells from 5 different donors.
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Effects of the inhibition of selected signaling pathways on the synthesis (secretion + 
intracellular levels) of IL-1β from human MD-PBMCs after 24 h exposure to TBT. A) MEK 
inhibitor (PD98059); B) p38 inhibitor (SB202190). An increase in secretion or in 
intracellular level is a number greater than 1 a decrease in secretion compared to the control 
is a number less than 1. The control is arbitrarily set at 1. Cells treated with inhibitor are 
compared to control cells treated with inhibitor. A combined fold increase (secretion + 
intracellular) greater than 1 indicates an increase in synthesis.
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Effects of 24 h TBT exposure to 50, 100, and 200 nM on IL-1β mRNA from monocyte-
depleted PBMCs treated with MAPK pathway inhibitors. A) MEK Inhibitor (PD98059) 
Donor F465; B) MEK Inhibitor (PD98059) Donor F479; C) p38 inhibitor (SB202190) 
Donor F479. Fold changes in mRNA levels compared to the appropriate control are shown 
above the bars. (+) indicates a significant increase (p<0.05) above the appropriate control 
and (*) indicates a significant decrease (p<0.05) compared to the appropriate control.
Brown et al. Page 16













Brown et al. Page 17














Effects of exposures to TBT on IL-6 synthesis in monocyte-depleted PBMCs. A) 30 minute 
exposure to 0–200 nM TBT. The blots with accompanying secretion data are shown for the 
cells from 4 different donors. An increase in secretion or in intracellular level is a number 
greater than 1 a decrease in secretion compared to the control is a number less than 1. The 
control is arbitrarily set at 1. A combined fold increase (secretion + intracellular) greater 
than 1 indicates an increase in synthesis. B) 6 h exposure to 0–200 nM TBT. The blots with 
accompanying secretion data are shown for the cells from 4 different donors. C) 24 h 
exposure to 0–200 nM TBT. The blots with accompanying secretion data are shown for the 
cells from 5 different donors.
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Effects of the inhibition of selected signaling pathways on the production (secretion + 
intracellular levels) of IL-6 from human MD-PBMCs after 24 h exposure to TBT. A) MEK 
inhibitor (PD98059); B) p38 inhibitor (SB202190). An increase in secretion or in 
intracellular level is a number greater than 1 a decrease in secretion compared to the control 
is a number less than 1. The control is arbitrarily set at 1. Cells treated with inhibitor are 
compared to control cells treated with inhibitor. A combined fold increase (secretion + 
intracellular) greater than 1 indicates an increase in synthesis.
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Effects of 24 h TBT exposure to 50, 100, and 200 nM on IL-6 mRNA from monocyte-
depleted PBMCs treated with MAPK pathway inhibitors. p38 inhibitor (SB202190) donor 
F480. Fold changes in mRNA levels compared to the appropriate control are shown above 
the bars. (+) indicates a significant increase (p<0.05) above the appropriate control and (*) 
indicates a significant decrease (p<0.05) compared to the appropriate control.
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Table 1
Effects of exposures to TBT on IL-1β mRNA levels in MD-PBMCs
6 h Interleukin 1 beta mRNA expression (AU)
[TBT] F340 F374 F393 F397
0 15±1 19±5 32±8 23±0
nM 2.5 18±2 28±12 35±24 32±25
5 18±1+ 24±4 23±2 41±0
0 18±0+ 20±1 14±5* 39±24
25 22±2+ 22±4 14±6* 50±36
50 22±5 44±20 27±7 44±10
100 23±3+ 34±13 28±14 26±5
200 22±3+ 20±3 1±0* 23±10
24 h Interleukin 1 beta mRNA expression (AU)
[TBT] F266 F277 F302 F322
0 11±1 15±1 22±1 9±1
nM 2.5 14±0+ 16±1 28±5 12±3
5 14±1+ 17±2 23±1 13±2
10 14±2 17±2 23±1 16±4
25 15±2+ 20±2+ 22±2 19±1+
50 17±2+ 29±3+ 24±1+ 21±6
100 26±3+ 36±5+ 31±2+ 30±2+
200 20±2+ 29±7 16±5 48±9+
Values are mean±S.D. of triplicate determinations. (+) Indicates a significant increase in secretion and (*) indicates a significant decrease compared 
to control cells, p<0.05.
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Table 2
Effects of exposures to TBT on IL-6 mRNA levels in MD-PBMCs
6 h Interleukin 6 mRNA expression (AU)
[TBT] F340 F374 F393 F397
0 33±6 35±7 26±5 21±3
nM 2.5 36±3 41±26 39±20 32±9
5 35±10 34±23 30±4 28±13
10 28±2 32±14 27±2 31±13
25 34±2 41±18 19±6 32±16
50 20±5* 44±30 31±7 18±10
100 29±3 32±4 31±9 30±5
200 26±5 10±3* 1±0* 26±3
24 h Interleukin 6 mRNA expression (AU)
[TBT] F266 F277 F302 F322
0 8±0 23±2 21±3 3±0
nM 2.5 10±1+ 28±6 21±6 4±1
5 10±1+ 18±2* 19±1 3±1
10 11±1+ 20±1 18±2 4±1
25 12±1+ 22±3 15±1 6±0+
50 16±1+ 33±7 24±3 3±3
100 50±6+ 36±3+ 33±4+ 19±3+
200 60±17+ 90±4+ 21±9 164±29+
Values are mean±S.D. of triplicate determinations. (+) Indicates a significant increase in secretion and (*) indicates a significant decrease compared 
to control cells, p<0.05.
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